procurement of drugs purchase of drugs (oncology, growth factor, antiemetic) , 1.01 to 1.02- 5-fluorouracile - (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , 5-fluorouracil , 5-fluorouracil , 2.01 to 2.02- 5-fluorouracil (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , 5-fluorouracil , 5-fluorouracil , 3.01 to 3.02- abemaciclib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , abemaciclib , abemaciclib , 4.01 to 4.02- bosutinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , bosutinib , bosutinib , 5.01 to 5.03- cabozantinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , cabozantinib , cabozantinib , cabozantinib , 6.01 to 6.03- carfilzomib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , carfilzomib , carfilzomib , carfilzomib , 7.01 to 7.02- chlorambucil (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , chlorambucil , chlorambucil , 8.01 to 8.03- cyclophosphamide powder (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , cyclophosphamide powder , cyclophosphamide powder , cyclophosphamide powder , 9.01 to 9.03- cyclophosphamide rtd (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , cyclophosphamide rtd , cyclophosphamide rtd , cyclophosphamide rtd , 10.1 to 10.3- dacarbazine (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , dacarbazine , dacarbazine , dacarbazine , 11.01 to 11.02- dacomitinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , dacomitinib , dacomitinib , 12.01 to 12.06- darbepoetin (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , darbepoetin , darbepoetin , darbepoetin , darbepoetin , darbepoetin , darbepoetin , 13.01 to 13.02- decitabine (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , decitabine , decitabine , 14.01 to 14.02- durvalumab (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , durvalumab , durvalumab , 15.01 to 15.04- everolimus (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , everolimus , everolimus , everolimus , everolimus , 16.01 to 16.02- everolimus (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , everolimus , everolimus , 17.01 to 17.02- l-asparaginase (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , l-asparaginase , l-asparaginase , 18.01 to 18.02- lorlatinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , lorlatinib , lorlatinib , 19.01 to 19.02 -luspatercept (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , luspatercept , luspatercept , 20.01 to 20.02 -megestrol (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , megestrol , megestrol , 21.01 to 21.03 - mitomycin-c (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , mitomycin-c , mitomycin-c , mitomycin-c , 22.01 to 22.02- nanosomal paclitaxel lipid suspension (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , nanosomal paclitaxel lipid suspension (npls) for inj , nanosomal paclitaxel lipid suspension (npls) for inj , 23.01 to 23.02 - nilotinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , nilotinib , nilotinib , 24.01 to 24.02 -nintedanib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , nintedanib , nintedanib , 25.01 to 25.02- octreotide (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , octreotide , octreotide , 26.01 to 26.03- octreotide lar (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , octreotide lar , octreotide lar , octreotide lar , 27.01 to 27.02 -olaparib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , olaparib , olaparib , 28.01 to 28.02- osimertinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , osimertinib , osimertinib , 29.01 to 29.03- pegylated interferon alfa 2b (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , pegylated interferon alfa 2b , pegylated interferon alfa 2b , pegylated interferon alfa 2b , 30.01 to 30.02- pertuzumab+trastuzumab (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , pertuzumab+trastuzumab , pertuzumab+trastuzumab , 31.01 to 31.02- polatuzumab vedotin (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , polatuzumab vedotin , polatuzumab vedotin , 32.01 to 32.03 - pomalidomide (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , pomalidomide , pomalidomide , pomalidomide , 33.01 to 33.02 - ramucirumab (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , ramucirumab , ramucirumab , 34.01 to 34.02- recombinant human interferon alfa 2b(quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , recombinant human interferon alfa 2b , recombinant human interferon alfa 2b , 35.01 to 35.02- rucaparib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , rucaparib , rucaparib , 36.01 to 36.03- ruxolitinib (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , ruxolitinib , ruxolitinib , ruxolitinib , 37.01 to 37.02 -teclistamab (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , teclistamab , teclistamab , 38.01 to 38.02 -s1 therapy tegfur+gimeracil+oteracil (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , s1 therapy tegfur+gimeracil+oteracil , s1 therapy tegfur+gimeracil+oteracil , 39.01 to 39.02- thalidomide (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , thalidomide , thalidomide , 40.01 to 40.03- tocilizumab (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , tocilizumab , tocilizumab , tocilizumab , 41.01 to 41.03- venetoclax (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , venetoclax , venetoclax , venetoclax , 42.01 to 42.02- vinorelbine (quoting for all strength is preferable, technically shortlisted innovators/originals , l1 & l2 will be selected based on consolidated results) , vinorelbine , vinorelbine , name of the items , acalabrutinib , alectinib , all trans retinoic acid(tretinoin) , alpelisib , alpelisib , alteplase , amivantamab , amphotericin b liposomal in ns , anastrozole , apalutamide , arsenic trioxide , asciminib , atezolizumab , avelumab , bicalutamide , bleomycin , bortezomib , brentuximab vedotin , busulphan , busulphan , cabazitaxel , capecitabine+cyclophosphamide , capecitabine+cyclophosphamide , capmatinib , carmustine , ceritinib , cetuximab , cladribine , clofarabine , cyclophosphamide , dabrafenib , dabrafenib , dactinomycin , daratumumab+hyaluronidase fihj subcutaneous , darolutamide , daunorubicin , docetaxel nanosomal(lipid suspension) , docetaxel nanosomal(lipid suspension) , docetaxel nanosomal(lipid suspension) , entrectinib , entrectinib , enfortumab vedotin , enfortumab vedotin , enzalutamide syrup 150 ml , eribulin , erythropoietin , erythropoietin , erythropoietin , erythropoietin , erythropoietin , erythropoietin , erythropoietin , erythropoietin , estramustine , etoposide , factor vii eptacog alfa(human recombinant coagulation factor vii activated r-dna origin) , factor vii eptacog alfa(human recombinant coagulation factor vii activated r-dna origin) , fludarabine , fludarabine , flunarizine , flutamide , fosaprepitant dimeglumine , fosfestrol , fosnetupitant+palonosetron , gliteritinib , granisetron , granisetron , granisetron md , goserelin , goserelin , hydroxyurea , hydroxyurea , ibandronic acid , ibandronic acid , ibandronic acid , ibrutinib , idarubicin , infleximab , inotuzumab ozogamicin , interferon alpha 2b , ipilimumab , irinotecan liposomal , isavuconazole , isavuconazole , leucovorin calcium , leucovorin calcium , leucovorin calcium , leuprolide acetate , lomustine , melphalan , melphalan , melphalan , mercaptopurine , mercaptopurine 100 ml , mesna (3*2 ml pack) inj , mesna 1*2 ml inj , mesna respiratory solution , methotrexate , methotrexate , methotrexate , methotrexate , methotrexate , methotrexate , midostaurin , mitoxantrone , mycobacterium w.(heat killed) immunomodulator inj , nelarabine , nimotuzumab , obinutuzumab , ondansetron , ondansetron , ondansetron , ondansetron , ondansetron 30 ml syrup , ondansetron md , ondansetron md , ondansetron ods , ondansetron ods , paclitaxel albumin bound nano particle , palanosetron , palanosetron , palanosetron , palanosetron+netupitant , palanosetron+netupitant , panitumumab , pegaspargase , pembrolizumab , pertuzumab , plerixafor , procarbazine , rasburicase , regorafenib , relugolix , ribociclib , romiplostim , sargramostim , sirolimus , sorafenib , tamoxifen , tamoxifen , tegfur+uracil , tepotinib , thioguanine , thiotepa , thiotepa , thyrotropin alfa , topotecan , toripalimab , trabectedin , trametinib , trastuzumab deruxtecan , trifluridine+tipiracil , trifluridine+tipiracil , triptorelin , triptorelin , triptorelin pamoate , tremelimumab , tucatinib , tucatinib , valganciclovir , vinblastin , vincristine , vincristine , voriconazole , zoledronic acid , zoledronic acid